TY  - JOUR
AU  - Steinacker, Petra
AU  - Anderl-Straub, Sarah
AU  - Diehl-Schmid, Janine
AU  - Semler, Elisa
AU  - Uttner, Ingo
AU  - von Arnim, Christine A F
AU  - Barthel, Henryk
AU  - Danek, Adrian
AU  - Fassbender, Klaus
AU  - Fliessbach, Klaus
AU  - Foerstl, Hans
AU  - Grimmer, Timo
AU  - Huppertz, Hans-Jürgen
AU  - Jahn, Holger
AU  - Kassubek, Jan
AU  - Kornhuber, Johannes
AU  - Landwehrmeyer, Bernhard
AU  - Lauer, Martin
AU  - Maler, Juan Manuel
AU  - Mayer, Benjamin
AU  - Oeckl, Patrick
AU  - Prudlo, Johannes
AU  - Schneider, Anja
AU  - Volk, Alexander E
AU  - Wiltfang, Jens
AU  - Schroeter, Matthias L
AU  - Ludolph, Albert C
AU  - Otto, Markus
AU  - group, FTLDc study
AU  - Albrecht, Franziska
AU  - Bisenius, Sandrine
AU  - Feneberg, Emily
AU  - Haefner, Sibylle
AU  - Kasper, Elisabeth
AU  - Kurzwelly, Delia
AU  - Lampe, Leonie
AU  - Levin, Johannes
AU  - Lornsen, Finn
AU  - Luley, Maxine
AU  - Oberstein, Timo
AU  - Pellkofer, Hannah
AU  - Prix, Catharina
AU  - Richter-Schmidinger, Tanja
AU  - Roth, Nina
AU  - Sabri, Osama
AU  - Schachner, Lisa
AU  - Schomburg, Robert
AU  - Schönecker, Sonja
AU  - Schuemberg, Katharina
AU  - Spottke, Annika
AU  - Teipel, Stefan
AU  - Wilken, Petra
AU  - Zech, Heike
TI  - Serum neurofilament light chain in behavioral variant frontotemporal dementia.
JO  - Neurology
VL  - 91
IS  - 15
SN  - 0028-3878
CY  - [S.l.]
PB  - Ovid
M1  - DZNE-2020-06698
SP  - e1390-e1401
PY  - 2018
AB  - Objective: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).Methods: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration–related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry.Results: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91
KW  - Aged
KW  - Alzheimer Disease: blood
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: diagnostic imaging
KW  - Alzheimer Disease: genetics
KW  - Atrophy
KW  - Biomarkers: blood
KW  - Biomarkers: cerebrospinal fluid
KW  - Brain: pathology
KW  - Cognitive Dysfunction: blood
KW  - Cognitive Dysfunction: cerebrospinal fluid
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Cognitive Dysfunction: genetics
KW  - Diagnosis, Differential
KW  - Disease Progression
KW  - Female
KW  - Follow-Up Studies
KW  - Frontotemporal Dementia: blood
KW  - Frontotemporal Dementia: diagnostic imaging
KW  - Frontotemporal Dementia: genetics
KW  - Frontotemporal Dementia: pathology
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neurofilament Proteins: blood
KW  - Organ Size
KW  - Prospective Studies
KW  - Biomarkers (NLM Chemicals)
KW  - Neurofilament Proteins (NLM Chemicals)
KW  - neurofilament protein L (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:30209235
DO  - DOI:10.1212/WNL.0000000000006318
UR  - https://pub.dzne.de/record/140376
ER  -